Benefits
Zero-calorie sugar replacement
Steviol glycosides are 200-300× sweeter than sucrose with negligible caloric contribution. Used in beverages, baked goods, dietary products. Heat-stable up to baking temperatures. Most commercial 'stevia' products are blends with erythritol, maltodextrin, or other bulking agents — pure stevia is impractical for cup-for-cup baking substitution.
Glycemic neutrality
Multiple RCTs confirm steviol glycosides produce no significant blood glucose or insulin response in diabetic and non-diabetic populations. Consistent across single-dose and chronic-exposure studies. Reasonable sugar replacement for diabetics and prediabetics with awareness of potential microbiome effects (see below).
Modest blood pressure effects (mixed evidence)
Some trials in hypertensive patients suggest stevia leaf extract modestly reduces blood pressure. Effect not consistent across studies — varies with stevia preparation (whole leaf vs purified glycosides) and population. Not validated as antihypertensive intervention; possible minor benefit in some users.
Gut microbiome — altered but inconsistent
Suez 2022 (Cell, randomized human trial) included stevia among 4 non-nutritive sweeteners tested in healthy adults × 2 weeks. Stevia produced significant microbiome composition shifts and modest glycemic alterations in some individuals. Effect was individual-microbiome-specific. Less concerning than sucralose/saccharin findings but notable for a 'natural' sweetener.
WHO 2023 non-sugar sweeteners guideline
WHO 2023 conditional recommendation against using non-sugar sweeteners for weight control or NCD risk reduction includes stevia. Based on systematic review showing no long-term benefit for body weight/composition and possible association with type 2 diabetes and cardiovascular disease. Reframes public health framing of all NSS, including 'natural' options.
Dental and cariogenicity profile
Streptococcus mutans cannot ferment steviol glycosides — non-cariogenic. Some preliminary evidence of mild antibacterial effects on oral pathogens. Reasonable component of sugar-free oral care products and dental health-conscious sweetening.
Forms and regulatory framework
FDA GRAS applies to high-purity steviol glycosides (mainly rebaudioside A and stevioside). Whole stevia leaf and crude leaf extract are not FDA-approved as sweeteners (only purified glycosides). Most commercial 'stevia' products are stevia leaf extract with bulking agents. Bitter aftertaste varies by glycoside profile — Reb A is sweeter and cleaner-tasting than stevioside.
Mechanism of action
Sweet taste receptor activation
Steviol glycosides bind the T1R2/T1R3 heterodimeric sweet taste receptor on tongue taste buds, generating a sweet sensation 200-400× more potent per molecule than sucrose. Different glycosides bind with slightly different kinetics — explaining the taste differences between stevioside (more licorice-like aftertaste), Reb A (cleaner but with detectable bitterness), and Reb M/Reb D (cleanest, most sucrose-like profile).
Non-absorption of intact glycosides
Steviol glycosides are not absorbed intact in the small intestine. They reach the colon where gut bacteria — primarily Bacteroides species — hydrolyze the glucose units to release steviol (the aglycone). Steviol is absorbed, conjugated to steviol glucuronide in the liver, and excreted predominantly in urine. This explains why steviol glycosides contribute no calories and don't raise blood glucose — the sweet molecule never reaches systemic circulation in its intact form.
Why steviol glycosides interact with the microbiome
Because gut bacteria are required to release steviol from the glycoside, steviol glycoside intake represents a substrate for specific microbial taxa. Repeated exposure can shift microbial composition toward those that metabolize the substrate. This is the mechanistic basis for the microbiome-altering effect documented in Suez 2022 (Cell, PMID 35987212) — a real biological signal, with downstream glycemic significance still being characterized.
Hypotensive mechanism (calcium channel modulation)
Stevioside has been shown in animal and isolated tissue studies to modulate vascular smooth muscle calcium channels and decrease vascular tone — the proposed mechanism for the modest blood pressure reduction observed at high doses. Effect is dose-dependent and unlikely to be clinically meaningful at typical sweetener intakes.
Clinical trials
Multi-arm clinical trial in 120 healthy NSS-naive adults randomized to 2 weeks of saccharin, sucralose, aspartame, stevia, or control at sub-ADI doses.
Clinical population described in trial publication.
Multi-arm clinical trial in 120 healthy NSS-naive adults randomized to 2 weeks of saccharin, sucralose, aspartame, stevia, or control at sub-ADI doses. All four NSS distinctly altered stool and oral microbiome and plasma metabolome. Saccharin and sucralose impaired glycemic responses to oral glucose challenge; stevia and aspartame did not in this trial. Fecal microbiome transplant from human responders to germ-free mice transferred the glycemic phenotype — establishing causation. Important nuance: stevia altered the microbiome without measurable glycemic consequence at the doses and duration studied.
Two-year randomized double-blind placebo-controlled trial in 168 hypertensive Taiwanese adults randomized to stevioside 1500 mg/day or placebo.
Clinical population described in trial publication.
Two-year randomized double-blind placebo-controlled trial in 168 hypertensive Taiwanese adults randomized to stevioside 1500 mg/day or placebo. Significant systolic and diastolic blood pressure reduction in the stevioside arm sustained over 2 years. Notable for trial duration but not consistently replicated at lower typical-use doses; relevance for sweetener-level intake (typically <100 mg/day stevioside equivalent) is limited.
European Food Safety Authority FAF Panel evaluated proposed ADI modification from 4 to 6 or 16 mg/kg body weight/day steviol equivalents.
Clinical population described in trial publication.
European Food Safety Authority FAF Panel evaluated proposed ADI modification from 4 to 6 or 16 mg/kg body weight/day steviol equivalents. Confirmed the existing ADI of 4 mg/kg/day remains appropriate based on available toxicological evidence. Currently authorized in the EU across 32 food categories. EFSA 2021 and 2022 opinions covered the safety of enzymatically-produced rebaudiosides M, D, and AM.
Conditionally recommended against using non-sugar sweeteners for weight control or to reduce risk of NCDs in adults or children.
Clinical population described in trial publication.
Conditionally recommended against using non-sugar sweeteners for weight control or to reduce risk of NCDs in adults or children. Based on evidence reviews finding limited long-term weight-loss benefit in clinical trials and possible associations with type 2 diabetes, cardiovascular disease, and all-cause mortality in observational studies. Applies to stevia along with all other NSS. published a critique arguing the recommendation underweighted clinical trial substitution-effect evidence relative to observational data.